Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4

Cited by (1,000)

Items 501–600 of 1,000

1. Lisinopril inhibits nuclear transcription factor kappa B and augments sensitivity to silymarin in experimental liver fibrosis
   Sameh Saber, Reham M. Goda, Ghada S. El‐Tanbouly, Dalia Ezzat · 2018 · International Immunopharmacology
2. Hepatic stellate cells – from past till present: morphology, human markers, human cell lines, behavior in normal and liver pathology
   Rada Teodora Suflețel, Carmen Stanca Melincovici, Bogdan‐Alexandru Gheban, Toader Zaharie, Carmen Mihaela Mihu · 2021 · Romanian Journal of Morphology and Embryology
3. Oral–Gut Microbiome Axis in Gastrointestinal Disease and Cancer
   Se-Young Park, Byeong-Oh Hwang, Mihwa Lim, Seung Ho Ok, Sun Lee, Kyung‐Soo Chun, Kwang-Kyun Park, Yinling Hu, Won‐Yoon Chung, Na‐Young Song · 2021 · Cancers
4. Cancer-Associated Microbiota: From Mechanisms of Disease Causation to Microbiota-Centric Anti-Cancer Approaches
   Priyankar Dey, Saumya Ray Chaudhuri · 2022 · Biology
5. San-Wu-Huang-Qin decoction attenuates tumorigenesis and mucosal barrier impairment in the AOM/DSS model by targeting gut microbiome
   Yelu Zhou, Yuanyuan Feng, Rong Cen, Xinxin Hou, Hao Nao Yu, Jian Sun, Lihong Zhou, Qing Ji, Ling Zhao, Yan Wang et al. · 2022 · Phytomedicine
6. Molecular Targets in Hepatocarcinogenesis and Implications for Therapy
   Meng‐Yu Wu, Giuo-Teng Yiang, Pei‐Wen Cheng, Pei‐Yi Chu, Chia‐Jung Li · 2018 · Journal of Clinical Medicine
7. Baishouwu Extract Suppresses the Development of Hepatocellular Carcinoma via TLR4/MyD88/NF-κB Pathway
   Yongfang Ding, Zixuan Peng, Lan Ding, Yunru Peng · 2019 · Frontiers in Pharmacology
8. Over-expression of MiR-122 promotes apoptosis of hepatocellular carcinoma via targeting TLR4
   Xiaolin Wei, Hui Liu, Xiaowu Li, Xiangde Liu · 2019 · Annals of Hepatology
9. Bacterial Extracellular Vesicles in Gastrointestinal Tract Cancer: An Unexplored Territory
   Sajeen Bahadur Amatya, Sonja Salmi, Veera Kainulainen, Peeter Karihtala, Justus Reunanen · 2021 · Cancers
10. Hepatic Fibrosis and Cirrhosis
    Don C. Rockey · 2015 · Wiley eBooks
11. The Role of Gut Microbiota-Bile Acids Axis in the Progression of Non-alcoholic Fatty Liver Disease
    Yiming Ni, Mengna Lu, Yuan Xu, Qixue Wang, Xinyi Gu, Ying Li, Tongxi Zhuang, Chenyi Xia, Ting Zhang, Xiaojun Gou et al. · 2022 · Frontiers in Microbiology
12. Mechanisms of hepatocellular carcinoma and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B
    Saisai Zhang, Lung‐Yi Mak, Man‐Fung Yuen, Wai‐Kay Seto · 2024 · Clinical and Molecular Hepatology
13. Dysregulation of gut microbiota stimulates NETs-driven HCC intrahepatic metastasis: therapeutic implications of healthy faecal microbiota transplantation
    Zhe Deng, Si Mei, Zhaoguang Ouyang, Ruoyu Wang, Lihuai Wang, Bo Zou, Jingjing Dai, Kexin Mao, Qian Li, Qianqian Guo et al. · 2025 · Gut Microbes
14. A pro-tumorigenic function of S100A8/A9 in carcinogen-induced hepatocellular carcinoma
    Aurora De Ponti, Lars Wiechert, Doris Schneller, Tobias Pusterla, Thomas Longerich, Nancy Hogg, Arndt Vogel, Peter Schirmacher, Jochen Heß, Peter E. Angel · 2015 · Cancer Letters
15. Immune response involved in liver damage and the activation of hepatic progenitor cells during liver tumorigenesis
    Xiaojuan Hou, Fei Ye, Xiaoyong Li, Wenting Liu, Yingying Jing, Zhipeng Han, Lixin Wei · 2017 · Cellular Immunology
16. Regulation of Hepatic Inflammation via Macrophage Cell Death
    Zhuan Li, Steven A. Weinman · 2018 · Seminars in Liver Disease
17. Seven immune‐related genes prognostic power and correlation with tumor‐infiltrating immune cells in hepatocellular carcinoma
    Tiantian Liu, Hao Wu, Jianni Qi, Chengyong Qin, Qiang Zhu · 2020 · Cancer Medicine
18. Human Gut Microbiome and Liver Diseases: From Correlation to Causation
    Rui Li, Zhengsheng Mao, Xujun Ye, Tao Zuo · 2021 · Microorganisms
19. Lipopolysaccharide supports maintaining the stemness of CD133+ hepatoma cells through activation of the NF-κB/HIF-1α pathway
    Fobao Lai, Wenting Liu, Yingying Jing, Guofeng Yu, Zhipeng Han, Xue Feng Yang, Jianxing Zeng, Hangjie Zhang, Rongyu Shi, Xiaoyong Li et al. · 2016 · Cancer Letters
20. Gut Microbiome and Gastrointestinal Cancer
    Nurdan A. Tozun, Eser Vardareli · 2016 · Journal of Clinical Gastroenterology
21. Small-Molecule Modulators Targeting Toll-like Receptors for Potential Anticancer Therapeutics
    Jiayu Wang, Jifa Zhang, Jiaxing Wang, Xinyue Hu, Liang Ouyang, Yuxi Wang · 2023 · Journal of Medicinal Chemistry
22. Microbial metabolites are involved in tumorigenesis and development by regulating immune responses
    Jiahui Liu, Ruxian Tian, Caiyu Sun, Ying Guo, Lei Dong, Yumei Li, Xicheng Song · 2023 · Frontiers in Immunology
23. TIFA, an inflammatory signaling adaptor, is tumor suppressive for liver cancer
    Wenzhi Shen, Antao Chang, Jingfan Wang, W Zhou, Ruifang Gao, J Li, Y Xu, Xin Luo, Rong Xiang, Na Luo et al. · 2015 · Oncogenesis
24. Fibroblast Growth Factor 15/19 in Hepatocarcinogenesis
    Gloria Álvarez‐Sola, Iker Uriarte, Maria Ujue Latasa, Raquel Urtasun, Marina Bárcena‐Varela, María Elizalde, Maddalen Jiménez, Carlos M. Rodríguez‐Ortigosa, Fernando José Corrales, Maite G. Fernández‐Barrena et al. · 2017 · Digestive Diseases
25. NADPH oxidase 4 modulates hepatic responses to lipopolysaccharide mediated by Toll-like receptor-4
    Anand Narayan Singh, Bhargav Koduru, Cameron Carlisle, Hasina Akhter, Rui-Ming Liu, Katrin Schröder, Ralf Peter Brandes, David M. Ojcius · 2017 · Scientific Reports
26. Reduced Endoplasmic Reticulum Stress-Mediated Autophagy Is Required for Leptin Alleviating Inflammation in Adipose Tissue
    Lu Gan, Zhenjiang Liu, Dan Luo, Qian Ren, Hua Wu, Changxing Li, Chao Sun · 2017 · Frontiers in Immunology
27. Human Toll-Like Receptor 4 (hTLR4): Structural and functional dynamics in cancer
    Vinita Mishra, Chandramani Pathak · 2018 · International Journal of Biological Macromolecules
28. Recent Insights Into the Multiple Pathways Driving Non-alcoholic Steatohepatitis-Derived Hepatocellular Carcinoma
    Kazuki Takakura, Tsunekazu Oikawa, Masanori Nakano, Chisato Saeki, Yuichi Torisu, Mikio Kajihara, Masayuki Saruta · 2019 · Frontiers in Oncology
29. Current and Future Treatments in the Fight against Non-Alcoholic Fatty Liver Disease
    Benoit Smeuninx, Ebru Boslem, Mark Anthony Febbraio · 2020 · Cancers
30. The role of gut microbiome in chemical-induced metabolic and toxicological murine disease models
    Priyankar Dey · 2020 · Life Sciences
31. Pattern Recognition Receptors: Significance of Expression in the Liver
    J Zeromski, Agata Kierepa, Bartosz Brzezicha, Arleta Elżbieta Kowala-Piaskowska, Iwona Mozer‐Lisewska · 2020 · Archivum Immunologiae et Therapiae Experimentalis
32. Gut Microbiome Signatures in the Progression of Hepatitis B Virus-Induced Liver Disease
    Ranxi Li, Xinzhu Yi, Junhao Yang, Zhou Zhu, Yifei Wang, Xiaomin Liu, Xili Huang, Yu Wan, Xihua Fu, Wensheng Shu et al. · 2022 · Frontiers in Microbiology
33. Targeting the Gut–Liver Axis in Cirrhosis: Antibiotics and Non-Selective β-Blockers
    Madsen, Bjørn S., Havelund, Troels, Krag, Aleksander · 2013 · Advances in Therapy
34. Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma
    Zeynep Akbulut, Başak Aru, Furkan Aydın, Gülderen Yanıkkaya Demirel · 2024 · Frontiers in Immunology
35. Lipopolysaccharide, arbiter of the gut–liver axis, modulates hepatic cell pathophysiology in alcoholism
    Ki Mark Mak, Aditya C. Shekhar · 2024 · The Anatomical Record
36. Dysbiosis and extraintestinal cancers
    Rui He, Pingqian Qi, Lin-Zhen Shu, Yidan Ding, Peng Zeng, Guosheng Wen, Ying Xiong, Huan Deng · 2025 · Journal of Experimental & Clinical Cancer Research
37. Effect of Lipopolysaccharide on the Progression of Non‐Alcoholic Fatty Liver Disease in High Caloric Diet‐Fed Mice
    Noriko Matsushita, T. Osaka, Ikuko Haruta, Hidehiro Ueshiba, Naoko Yanagisawa, Miyuki Omori‐Miyake, Etsuko Hashimoto, Noriyuki Shibata, Katsutoshi Tokushige, Kayoko Saito et al. · 2015 · Scandinavian Journal of Immunology
38. Microbiota, Epithelium, Inflammation, and TGF-β Signaling: An Intricate Interaction in Oncogenesis
    Xin Pang, Ya-jie Tang, Xiaohua Ren, Qianming Chen, Ya‐ling Tang, Xin‐hua Liang · 2018 · Frontiers in Microbiology
39. Characterization of native knee microorganisms using next-generation sequencing in patients undergoing primary total knee arthroplasty
    Michael T. Torchia, Ikechukwu C. Amakiri, Paul M. Werth, Wayne E. Moschetti · 2020 · The Knee
40. Epigallocatechin Gallate Induces Hepatic Stellate Cell Senescence and Attenuates Development of Hepatocellular Carcinoma
    Mozhdeh Sojoodi, Lan Wei, Derek J. Erstad, Suguru Yamada, Tsutomu Fujii, Hadassa Hirschfield, Rosa S. Kim, Gregory Yves Lauwers, Michael D. Lanuti, Yujin Hoshida et al. · 2020 · Cancer Prevention Research
41. Gut Microbiota and Liver Interaction through Immune System Cross-Talk: A Comprehensive Review at the Time of the SARS-CoV-2 Pandemic
    Emidio Scarpellini, Sharmila Fagoonee, Emanuele Rinninella, Carlo Rasetti, Isabella Aquila, Tiziana Larussa, Pietrantonio Ricci, Francesco Luzza, Ludovico Abenavoli · 2020 · Journal of Clinical Medicine
42. Liver Fibrosis—From Mechanisms of Injury to Modulation of Disease
    Christian Liedtke, Yulia Alexandrowna Nevzorova, Tom Luedde, Henning Wolfgang Zimmermann, Daniela C. Kroy, Pavel Strnad, Marie‐Luise Berres, Jürgen Bernhagen, Frank Tacke, Jacob Nattermann et al. · 2022 · Frontiers in Medicine
43. Targeting NF-κB pathway by dietary lignans in inflammation: expanding roles of gut microbiota and metabolites
    Dan Li, Feijun Luo, Tianyi Guo, Shuai Han, Hanqing Wang, Qinlu Lin · 2022 · Critical Reviews in Food Science and Nutrition
44. Research Progress of Fecal Microbiota Transplantation in Liver Diseases
    Yuanyuan Zhao, Gong Chen, Jing Xu, Dong Chen, Bo Yang, Zhishui Chen, Lai Wei · 2023 · Journal of Clinical Medicine
45. Echinacea purpurea polysaccharide intervene in hepatocellular carcinoma via modulation of gut microbiota to inhibit TLR4/NF-κB pathway
    Gaoxiang Jing, Wenqian Xu, Wei Ma, Yu Qian, Hongkang Zhu, Chang Liu, Yuliang Cheng, Yahui Guo, He Qian · 2024 · International Journal of Biological Macromolecules
46. Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse
    Jesse D. Riordan, Joseph H. Nadeau · 2014 · Mammalian Genome
47. A Molecular-Level Landscape of Diet-Gut Microbiome Interactions: Toward Dietary Interventions Targeting Bacterial Genes
    Yueqiong Ni, Jun Li, Gianni Panagiotou · 2015 · mBio
48. Functional Microbiomics in Liver Transplantation: Identifying Novel Targets for Improving Allograft Outcomes
    Michael S. Kriss, Elizabeth C. Verna, Hugo R. Rosen, Catherine Lozupone · 2018 · Transplantation
49. NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome
    Anna Michelotti, Marco de Scordilli, Lorenza Palmero, Michela Guardascione, Mario Masala, Rossana Roncato, Luisa Foltran, Elena Ongaro, Fabio Puglisi · 2021 · Cells
50. The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: From molecular mechanisms to potential clinical implications
    Konstantinos Arvanitakis, Theocharis Koufakis, Kalliopi Kotsa, Georgios S. Germanidis · 2022 · Pharmacological Research
51. Immune Control in Hepatocellular Carcinoma Development and Progression: Role of Stromal Cells
    Martin Franz Sprinzl, Peter R. Galle · 2014 · Seminars in Liver Disease
52. The Bacterial Microbiota of Gastrointestinal Cancers: Role in Cancer Pathogenesis and Therapeutic Perspectives
    Lina Elsalem, Ahmad A. Jum’ah, Mahmoud A. Alfaqih, Osama Aloudat · 2020 · Clinical and Experimental Gastroenterology
53. Therapeutic implications of probiotics in microbiota dysbiosis: A special reference to the liver and oral cancers
    Deepti Singh, Mohammad Afsar Khan, Hifzur Rahman Siddique · 2021 · Life Sciences
54. Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases
    Jing Liu, Dakai Yang, Xiaojing Wang, Paul Tetteh Asare, Qingwen Zhang, Lixin Na, Lei Shao · 2022 · Frontiers in Cellular and Infection Microbiology
55. The Pathogenesis of HCC Driven by NASH and the Preventive and Therapeutic Effects of Natural Products
    Gaoxuan Shao, Ying Liu, Lu Lu, Guangtao Zhang, Wenjun Zhou, Tao Wu, Lei Wang, Hanchen Xu, Guang Ji · 2022 · Frontiers in Pharmacology
56. A gut bacterial signature in blood and liver tissue characterizes cirrhosis and hepatocellular carcinoma
    Maria Effenberger, Silvio Waschina, Christina Bronowski, Gregor Sturm, Oronzo Tassiello, Felix Sommer, Andreas Zollner, Christina Watschinger, Felix Grabherr, Ronald Gstir et al. · 2023 · Hepatology Communications
57. Role of T cells in liver metastasis
    Kejia Wu, Guozhu Zhang, Changbing Shen, Li Zhu, Chongyuan Yu, Kurt Sartorius, Wei Ding, Yong Jiang, Yunjie Lu · 2024 · Cell Death and Disease
58. Diet-Induced Obesity Enhances Progression of Hepatocellular Carcinoma through Tenascin-C/Toll-Like Receptor 4 Signaling
    Jennifer H. Benbow, Kyle J. Thompson, Heidi L. Cope, Elizabeth Brandon‐Warner, Catherine R. Culberson, Krista L. Bossi, Ting Li, Mark W. Russo, Keith S. Gersin, Iain H. McKillop et al. · 2015 · American Journal Of Pathology
59. Exploring the microbiota to better understand gastrointestinal cancers physiology
    Concetta Panebianco, Adele Potenza, Angelo Andriulli, Valerio Pazienza · 2018 · Clinical Chemistry and Laboratory Medicine (CCLM)
60. Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response
    Vaihere Delaune, Lorenzo A. Orci, Stéphanie Lacotte, Andrea Peloso, Jacques Schrenzel, Vladimir Lazarević, Christian Toso · 2018 · Expert Opinion on Biological Therapy
61. Gamma linolic acid regulates PHD2 mediated hypoxia and mitochondrial apoptosis in DEN induced Hepatocellular carcinoma
    Hong Cui, Feng Han, Ling Zhang, Li Wang, Mukesh Kumar · 2018 · Drug Design Development and Therapy
62. RNA-binding motif protein 43 (RBM43) suppresses hepatocellular carcinoma progression through modulation of cyclin B1 expression
    Huan Feng, Juan Liu, Yangyang Qiu, Yao Liu, Hexige Saiyin, Xiao Liang, Fen Zheng, Ying Wang, Deke Jiang, Ying Wang et al. · 2020 · Oncogene
63. Microbial dysbiosis and epigenetics modulation in cancer development – A chemopreventive approach
    Shafiul Haque, Ritu Raina, Nazia Afroze, Arif Hussain, Ahmad Alsulimani, Vineeta Singh, Bhartendu Nath Mishra, Sanjana Kaul, Ravindra Nath Kharwar · 2021 · Seminars in Cancer Biology
64. The TGF-β/NADPH Oxidases Axis in the Regulation of Liver Cell Biology in Health and Disease
    Macarena Herranz‐Itúrbide, Irene Peñuelas‐Haro, Rut Espinosa‐Sotelo, Esther Bertrán, Isabel Fabregat · 2021 · Cells
65. Retinoblastoma protein potentiates the innate immune response in hepatocytes: Significance for hepatocellular carcinoma
    Jack Hutcheson, Ryan J. Bourgo, Uthra Balaji, Adam Ertel, Agnieszka Katarzyna Witkiewicz, Erik S. Knudsen · 2014 · Hepatology
66. Microbiome and NAFLD: potential influence of aerobic fitness and lifestyle modification
    Matthew R. Panasevich, Willem T. Peppler, Daniel Barton Oerther, David Charles Wright, R. Scott Rector · 2017 · Physiological Genomics
67. Downregulation of toll-like receptor 4 induces suppressive effects on hepatitis B virus-related hepatocellular carcinoma via ERK1/2 signaling
    Yiting Wang, Jing Cai, Xiaoli Zeng, Yajie Chen, Wei Yan, Yuming Ouyang, Dan Xiao, Zhiming Zeng, Long Huang, Anwen Liu · 2015 · BMC Cancer
68. The Incidence Characteristics of Second Primary Malignancy after Diagnosis of Primary Colon and Rectal Cancer: A Population Based Study
    Xu Guan, Yinghu Jin, Yinggang Chen, Zheng Jiang, Zheng Liu, Zhixun Zhao, Peng Yan, Guiyu Wang, Xishan Wang · 2015 · PLoS ONE
69. Hypothesis: solid tumours behave as systemic metabolic dictators
    Yang‐Ming Lee, Wei‐Chun Chang, Wen‐Lung Ma · 2016 · Journal of Cellular and Molecular Medicine
70. (Z)-3,5,4′-Trimethoxystilbene Limits Hepatitis C and Cancer Pathophysiology by Blocking Microtubule Dynamics and Cell-Cycle Progression
    Charles B. Nguyen, Hari Shankar R. Kotturi, Gulam Waris, Altaf Mohammed, Parthasarathy Chandrakesan, Randal J. May, Sripathi M. Sureban, Nathaniel Weygant, Dongfeng Qu, Chinthalapally V. Rao et al. · 2016 · Cancer Research
71. Innate immunity and hepatocarcinoma: Can toll-like receptors open the door to oncogenesis?
    Jorge André Gomes Lopes · 2016 · World Journal of Hepatology
72. Renin–angiotensin system inhibition ameliorates CCl4-induced liver fibrosis in mice through the inactivation of nuclear transcription factor kappa B
    Sameh Saber, Amr A. A. Mahmoud, Noha Said Helal, Eman G El-Ahwany, Rasha Hassan Abdel-Ghany · 2018 · Canadian Journal of Physiology and Pharmacology
73. Spirulina inhibits hepatocellular carcinoma through activating p53 and apoptosis and suppressing oxidative stress and angiogenesis
    Yomna Ibrahim Mahmoud, Aya M.M. Shehata, Nagui Hassan Fares, Asmaa Ahmed Mahmoud · 2020 · Life Sciences
74. Gut microbiota mediated molecular events and therapy in liver diseases
    Xiaoqiang Qi, Ming Jun Yang, Joseph Stenberg, Rahul Dey, Leslie Fogwe, Muhammad Shawkat Alam, Eric T. Kimchi, Kevin F. Staveley-O’Carroll, Guangfu Li · 2020 · World Journal of Gastroenterology
75. Dual Role of TNF and LTα in Carcinogenesis as Implicated by Studies in Mice
    Ekaterina O. Gubernatorova, Almina I. Polinova, Mikhail Petropavlovskiy, Olga A. Namakanova, Alexandra D. Medvedovskaya, Ruslan V. Zvartsev, Georgij B. Telegin, Marina S. Drutskaya, Sergei A. Nedospasov · 2021 · Cancers
76. The Microbiome as a Potential Target for Therapeutic Manipulation in Pancreatic Cancer
    Rozana Abdul Rahman, Ángela Lamarca, Richard A Hubner, Juan W. Valle, Mairead Geraldine McNamara · 2021 · Cancers
77. Diet and gut microbiome in fatty liver and its associated liver cancer
    Yasi Pan, Xiang Zhang · 2021 · Journal of Gastroenterology and Hepatology
78. Role of NLRC5 in progression and reversal of hepatic fibrosis
    Xuejiao Liu, Yuting Wu, Yang Yang, Wanxia Li, Cheng Huang, Xiao‐Ming Meng, Jun Li · 2016 · Toxicology and Applied Pharmacology
79. Metabolic primary liver cancer in adults: risk factors and pathogenic mechanisms
    Simonetta Lugari, Enrica Baldelli, Amedeo Lonardo · 2023 · Metabolism and Target Organ Damage
80. Genital tract microbiota composition profiles and use of prebiotics and probiotics in gynaecological cancer prevention: review of the current evidence, the European Society of Gynaecological Oncology prevention committee statement
    Anita Mitra, Murat Gültekin, Laura Burney Ellis, Nicolò Bizzarri, Sarah Joanne Bowden, Nadja Taumberger, Taja Bracic, Pedro Vieira‐Baptista, Jalid Sehouli, Maria Kyrgiou · 2023 · The Lancet Microbe
81. MASLD-Related HCC—Update on Pathogenesis and Current Treatment Options
    Catherine Leyh, Jason D. Coombes, Hartmut Schmidt, Ali E. Canbay, Paul Peter Manka, Jan Best · 2024 · Journal of Personalized Medicine
82. The intestinal microbiome and surgical disease
    Monika A. Krezalek, Kinga B. Skowron, Kristina L. Guyton, Baddr A. Shakhsheer, Sanjiv K. Hyoju, John C. Alverdy · 2016 · Current Problems in Surgery
83. Implication of the intestinal microbiome in complications of cirrhosis
    Mamatha Bhat, Bianca Maria Arendt, Venkat Bhat, Eberhard L. Renner, Atul Humar, Johane P. Allard · 2016 · World Journal of Hepatology
84. Contributing Roles of CYP2E1 and Other Cytochrome P450 Isoforms in Alcohol-Related Tissue Injury and Carcinogenesis
    Byoung‐Joon Song, Mohamed A. Abdelmegeed, Young‐Eun Cho, Mohammed Danish Akbar, Johng Sik Rhim, Minkyung Song, James P. Hardwick · 2019 · Advances in experimental medicine and biology
85. Emerging role of microbiota in immunomodulation and cancer immunotherapy
    Raghwendra Pratap Singh, Hilal Bashir, Rashmi Kumar · 2020 · Seminars in Cancer Biology
86. Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy
    Yuqing He, Mengyao Lu, Jing Che, Qian Chu, Peng Zhang, Yuan Chen · 2021 · Frontiers in Oncology
87. Role of Intestinal Microbes in Chronic Liver Diseases
    Mengyi Xu, Kangkang Luo, Junjie Li, Yu Li, Yuxuan Zhang, Zhiyao Yuan, Qiang Xu, Xudong Wu · 2022 · International Journal of Molecular Sciences
88. Isoformic PD-1-mediated immunosuppression underlies resistance to PD-1 blockade in hepatocellular carcinoma patients
    Zhiwu Tan, Mei Sum Chiu, Xinxiang Yang, Ming Yue, Tan To Cheung, Dongyan Zhou, Yuewen Wang, Anthony W.H. Chan, Chi Wing Yan, Ka Yi Kwan et al. · 2022 · Gut
89. Microbiome and Metabolomics in Liver Cancer: Scientific Technology
    Raja Ganesan, Sang Jun Yoon, Ki Tae Suk · 2022 · International Journal of Molecular Sciences
90. Implication of Gut Microbiota in Human Health
    Imran Khan, Muhammad Yasir, Esam I. Azhar, Taha Abduallah Kumosani, Elie K. Barbour, Fehmida Bibi, Mohammad Amjad Kamal · 2014 · CNS & Neurological Disorders - Drug Targets
91. Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy
    Miles Cameron Andrews, Alexandre Reuben, Vancheswaran Gopalakrishnan, Jennifer Ann Wargo · 2018 · Frontiers in Immunology
92. Molecular Mechanisms Regulating Obesity-Associated Hepatocellular Carcinoma
    Yetirajam Rajesh, Devanand Sarkar · 2020 · Cancers
93. Gut microbiota in MAFLD: therapeutic and diagnostic implications
    Waleed Alghamdi, Mahmoud Hisham Mosli, Saleh A. Alqahtani · 2024 · Therapeutic Advances in Endocrinology and Metabolism
94. Hepatic stellate cell heterogeneity: Functional aspects and therapeutic implications
    Yana Geng, Robert F. Schwabe · 2025 · Hepatology
95. Microbiome and host crosstalk: A new paradigm to cancer therapy
    Ashutosh Kumar Singh, Namyashree Nayak, Preeti Rathi, Deepanshu Verma, Rohit Sharma, Ashun Chaudhary, Alka Agarwal, Yamini Bhusan Tripathi, Neha Garg · 2020 · Seminars in Cancer Biology
96. The Microbiome and Hepatocellular Carcinoma
    Puru Rattan, Carlos D. Minacapelli, Vinod K. Rustgi · 2020 · Liver Transplantation
97. Defining the temporal evolution of gut dysbiosis and inflammatory responses leading to hepatocellular carcinoma in Mdr2 −/− mouse model
    Jason Behary, Anita E. Raposo, Nadia M. L. Amorim, Huimin Zheng, Lan Gong, Emily McGovern, Jinbiao Chen, K. Liu, Julia Beretov, C. Theocharous et al. · 2021 · BMC Microbiology
98. Host–Microbiota Interactions in Liver Inflammation and Cancer
    Julie Giraud, Maya Saleh · 2021 · Cancers
99. Modulation of the Gut Microbiome to Improve Clinical Outcomes in Hepatocellular Carcinoma
    Sj Shen, Saroj Khatiwada, Jason Behary, Rachel Kim, Amany Zekry · 2022 · Cancers
100. Bibliometric study of immunotherapy for hepatocellular carcinoma
     Zhiyi Li, Ying Zhang, Baipan Zhang, Rui Guo, He Min-Hua, Ziling Liu, Lei Yang, Hong Wang · 2023 · Frontiers in Immunology